About: drug innovation

Eastern Europe diversity should be considered in EU-wide cancer plan

Having a pan-European cancer control plan is crucial, but some flexibility should be granted to member states in choosing which aspect to prioritise within the framework, said Linda Gibbs from Pfizer Oncology in an interview with EURACTIV.com.
Health 28-06-2019

New pharma boss: Next EU Commission should be clear on how to protect innovation

The next EU Commission should take a stronger position on innovation in the pharma sector, the new leader of the European Federation of Pharmaceutical Industries and Associations (EFPIA) told EURACTIV.com in an interview.
Health 21-01-2019

Discussion heats up over stockpiling of generic drugs under patent protection

The Commission has announced its intention to add a manufacturing waiver to supplementary protection certificates (SPC), as part of its upgraded 2015 Single Market Strategy.
Health 07-11-2018

Greek minister: Effective health and pharma policy needs stronger EU Commission role

A number of member states want the European Commission’s competences in health and pharma policy to be upgraded in order to face more effectively the rising challenges in the field, Greek health minister Andreas Ksanthos told EURACTIV.com in an interview.
Health 10-10-2018

New drugs: how much are governments paying for innovation?

The European healthcare sector is divided over the “actual value” EU governments pay for the authorised and partly public-funded novel drugs, compared to medicines already on the market.
Health 08-05-2018

Time to end fragmentation of EU healthcare, experts say

Experts are asking for a more collaborative approach in EU healthcare and greater involvement of the European Commission in order to face rising challenges and put patients at the core of decision-making.
Health 10-01-2018

Commission reassures ‘worried’ member states on Health Technology Assessment

The Commission’s upcoming proposal on Health Technology Assessment (HTA) will focus on clinical aspects and leave member states to decide on economic or ethical parts, a European Commission spokesperson told EURACTIV.com.